Daxia Cai

Abstract Background: Germ-line EGFR mutations are rare, and their clinical significance, particularly regarding response to tyrosine kinase inhibitors (TKIs), remains poorly defined. The EGFR V831H (also known as R831H) mutation is an exceptionally rare variant with constitutive activity, and data on its therapeutic sensitivity are scarce. Methods: We present a detailed case report of a patient with advanced non-small cell lung cancer (NSCLC) harboring a germ-line EGFR V831H mutation.

Back to Journals » Clinical, Cosmetic and Investigational Dermatology » Volume 18 Authors Zhu Y , Cai D, Jiang J, Tu J, Tian Z, Zhang X, Luo S, Wang Y Received 7 November 2024 Accepted for publication 13 March 2025 Published 22 March 2025 Volume 2025:18 Pages 699—707 DOI https://doi.org/10.2147/CCID.S505045 Checked for plagiarism Yes Review by Single anonymous peer review Peer reviewer comments 2 Editor who approved publication: Prof.

A Correction on Germ-line exon 21 EGFR V831H mutation in advanced NSCLC resistance to almonertinib: a case report By Cai D, Lou J, Zhu Y and Wang Y (2026). Front. Oncol. 16:1758636. doi: [10.3389/fonc.2026.1758636 There was a mistake in Table 1 as published. DateDiagnostic procedures/treatment 2020.6.4 A CT scan performed at the local hospital detected a mass in the right lower lung along with mediastinal lymphadenopathy.